Dr. Anna Moore has recently joined MSU as the Director of Precision Health Program and Assistant Dean at the College of Human Medicine after conducting research as a Professor of Radiology at Massachusetts General Hospital/Harvard Medical School for over 27 years. She received her M.S. degree in Chemistry from Moscow State University and obtained her Ph.D. degree in Bioorganic Chemistry from the Institute of Biochemistry, Russian Academy of Sciences. She started her research at the Center for Molecular Imaging Research at the Department of Radiology at MGH and her career path progressed from a postdoctoral fellow to a full Professor at Harvard Medical School. Her research in aimed at developing molecular imaging theranostic agents for cancer imaging and therapy. Her recent studies on image-guided therapy of metastatic breast cancer showed a unique way to eradicate this devastating disease and will soon enter clinical trials. She is a co-founder of TransCode Therapeutics, a company that is aimed at bringing these therapies into clinic.
Dr. Moore published her work in the most prestigious journals including Nature, Nature Medicine, Nature Biotechnology, PNAS, Cancer Research and others. She is a recipient of multiple grant awards from NIH and other funding agencies.
For her contribution to teaching courses at international meetings she was awarded with the “Outstanding Teacher Award” from the International Society for Magnetic Resonance in Medicine (ISMRM). She was elected twice as a Chair of the Cellular and Molecular Imaging study group at this society. She was awarded a Distinguished Investigator Award from the Academy of Radiology Research in 2014. As one of the major contributors to the field of Molecular Imaging she was elected as a Council Member of the Society for Molecular Imaging and worked toward creation of the World Molecular Imaging Society (WMIS) in 2011. She served two terms as a Member of the Board of Trustees of WMIS. She is the United States Regional Editor for Molecular Imaging and Biology, the official journal of WMIS. For her relentless service to the Society Dr. Moore was elected as a Fellow of the World Molecular Imaging Society.
Since joining MSU, Dr. Moore has been working on changing the approach to healthcare by focusing on disease prediction, prevention and early detection. Her research is aimed at elucidation of the disease pathways and biomarkers and discovery of novel therapies in conjunction with state-of-the-art imaging.
Industry Expertise (5)
Areas of Expertise (6)
Fellow of the World Molecular Imaging Society (professional)
The World Molecular Imaging Society is an international scientific educational organization dedicated to the understanding of biology and medicine through multimodal in vivo imaging of cellular and molecular events involved in normal and pathologic processes and utilization of quantitative molecular imaging in patient care.
Distinguished Investigator Award from the Academy of Radiology Research (professional)
This prestigious honor recognizes individuals for their accomplishments in the field of medical imaging.
Russian Academy of Sciences, Institute of Biochemistry: Ph.D, Bioorganic Chemistry 1989
Moscow State University: M.S., Chemistry 1985
- World Molecular Imaging Society
- Women in Molecular Imaging Network
Journal Articles (6)
Treatment of stage IV metastatic breast cancer patients is limited to palliative options and represents an unmet clinical need. Here, we demonstrate that pharmacological inhibition of miRNA-10b - a master regulator of metastatic cell viability - leads to elimination of distant metastases in a mouse model of metastatic breast cancer. This was achieved using the miRNA-10b inhibitory nanodrug, MN-anti-miR10b, which consists of magnetic nanoparticles, conjugated to LNA-based miR-10b antagomirs. Intravenous injection of MN-anti-miR10b into mice bearing lung, bone, and brain metastases from breast cancer resulted in selective accumulation of the nanodrug in metastatic tumor cells.
The underglycosylated mucin 1 tumor antigen (uMUC1) is a biomarker that forecasts the progression of adenocarcinomas. In this study, we evaluated the utility of a dual-modality molecular imaging approach based on targeting uMUC1 for monitoring chemotherapeutic response in a transgenic murine model of pancreatic cancer (KCM triple transgenic mice). An uMUC1-specific contrast agent (MN-EPPT) was synthesized for use with magnetic resonance imaging (MRI) and fluorescence optical imaging. It consisted of dextran-coated iron oxide nanoparticles conjugated to the near infrared fluorescent dye Cy5.5 and to a uMUC1-specific peptide (EPPT).
Information regarding the longevity of transplanted pancreatic islet grafts could provide valuable information for treatment options. In our previous studies, we showed that isolated autologous pancreatic islets could be labeled with iron oxide nanoparticles and monitored after transplantation using MRI. Here, we report on in vivo monitoring of a secondary damage that occurs at the later stages because of allogeneic immune rejection.
The therapeutic promise of microRNA (miRNA) in cancer has yet to be realized. In this study, we identified and therapeutically exploited a new role for miR-10b at the metastatic site, which links its overexpression to tumor cell viability and proliferation. In the protocol developed, we combined a miR-10b-inhibitory nanodrug with low-dose anthracycline to achieve complete durable regressions of metastatic disease in a murine model of metastatic breast cancer. Mechanistic investigations suggested a potent antiproliferative, proapoptotic effect of the nanodrug in the metastatic cells, potentiated by a cell-cycle arrest produced by administration of the low-dose anthracycline.
With the increased potential of RNA interference (RNAi) as a therapeutic strategy, new noninvasive methods for detection of siRNA delivery and silencing are urgently needed. Here we describe the development of dual-purpose probes for in vivo transfer of siRNA and the simultaneous imaging of its accumulation in tumors by high-resolution magnetic resonance imaging (MRI) and near-infrared in vivo optical imaging (NIRF). These probes consisted of magnetic nanoparticles labeled with a near-infrared dye and covalently linked to siRNA molecules specific for model or therapeutic targets.
Type 1 diabetes mellitus is characterized by the selective destruction of insulin-producing beta cells, which leads to a deficiency in insulin secretion and, as a result, to hyperglycemia. At present, transplantation of pancreatic islets is an emerging and promising clinical modality, which can render individuals with type 1 diabetes insulin independent without increasing the incidence of hypoglycemic events. To monitor transplantation efficiency and graft survival, reliable noninvasive imaging methods are needed. If such methods were introduced into the clinic, essential information could be obtained repeatedly and noninvasively.